{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:29:25Z","timestamp":1791944965894,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.xphs.2017.08.024","type":"journal-article","created":{"date-parts":[[2017,9,16]],"date-time":"2017-09-16T03:00:27Z","timestamp":1505530827000},"page":"3613-3622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: Enhanced Brain Distribution and Pharmacodynamics"],"prefix":"10.1016","volume":"106","author":[{"given":"Preeti","family":"Wavikar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Vavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7184","key":"10.1016\/j.xphs.2017.08.024_bib1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial","volume":"318","author":"R\u00f6sler","year":"1999","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.xphs.2017.08.024_bib2","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1517\/17425240802542690","article-title":"Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease","volume":"5","author":"Winblad","year":"2008","journal-title":"Expert Opin Drug Deliv"},{"issue":"6","key":"10.1016\/j.xphs.2017.08.024_bib3","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1021\/jm00180a022","article-title":"Relationship of octanol\/water partition coefficient and molecular weight to rat brain capillary permeability","volume":"23","author":"Levin","year":"1980","journal-title":"J\u00a0Med Chem"},{"issue":"2","key":"10.1016\/j.xphs.2017.08.024_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/1567201053586047","article-title":"Intranasal drug delivery for brain targeting","volume":"2","author":"Vyas","year":"2005","journal-title":"Curr Drug Deliv"},{"issue":"12","key":"10.1016\/j.xphs.2017.08.024_bib5","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1023\/A:1018947208597","article-title":"Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity","volume":"16","author":"Olivier","year":"1999","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2017.08.024_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3109\/08982104.2014.954129","article-title":"Rivastigmine-loaded in situ gelling nanostructured lipid carriers for nose to brain delivery","volume":"25","author":"Wavikar","year":"2015","journal-title":"J\u00a0Liposome Res"},{"key":"10.1016\/j.xphs.2017.08.024_bib7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.colsurfb.2012.08.058","article-title":"Solid lipid nanoparticles as delivery systems for gambogenic acid","volume":"102","author":"Huang","year":"2013","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"3","key":"10.1016\/j.xphs.2017.08.024_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1166\/jbn.2014.1719","article-title":"Novel L-Lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer's disease","volume":"10","author":"Pagar","year":"2014","journal-title":"J\u00a0Biomed Nanotechnol"},{"issue":"2","key":"10.1016\/j.xphs.2017.08.024_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejpb.2010.07.007","article-title":"Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in\u00a0vitro and pharmacodynamic studies","volume":"76","author":"Joshi","year":"2010","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2017.08.024_bib10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejpb.2015.08.008","article-title":"Intranasal microemulsion for targeted nose to brain delivery in neurocysticercosis: role of docosahexaenoic acid","volume":"96","author":"Shinde","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"10.1016\/j.xphs.2017.08.024_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxlet.2009.05.020","article-title":"Toxicity and penetration of TiO2 nanoparticles in hairless mice and porcine skin after subchronic dermal exposure","volume":"191","author":"Wu","year":"2009","journal-title":"Toxicol Lett"},{"issue":"11","key":"10.1016\/j.xphs.2017.08.024_bib12","first-page":"1045","article-title":"Lowering of sodium deoxycholate-induced nasal ciliotoxicity with cyclodextrins","volume":"22","author":"Zhang","year":"2001","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"10.1016\/j.xphs.2017.08.024_bib13","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/1061186X.2012.716845","article-title":"Nanostructured lipid carriers system: recent advances in drug delivery","volume":"20","author":"Iqbal","year":"2012","journal-title":"J\u00a0Drug Target"},{"key":"10.1016\/j.xphs.2017.08.024_bib14","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations","volume":"54","author":"M\u00fcller","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"Suppl 2","key":"10.1016\/j.xphs.2017.08.024_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1289\/ehp.98106485","article-title":"In\u00a0vitro alternatives for ocular irritation","volume":"106","author":"Curren","year":"1998","journal-title":"Environ Health Perspect"},{"issue":"6","key":"10.1016\/j.xphs.2017.08.024_bib16","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/jps.20627","article-title":"In\u00a0vitro hemolysis: guidance for the pharmaceutical scientist","volume":"95","author":"Amin","year":"2006","journal-title":"J\u00a0Pharm Sci"},{"issue":"7","key":"10.1016\/j.xphs.2017.08.024_bib17","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1124\/dmd.112.044925","article-title":"Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance","volume":"40","author":"Kadam","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.xphs.2017.08.024_bib18","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.xphs.2017.08.024_bib19","unstructured":"U.S. Food and Drug Administration. Guidance for Industry: bioanalytical method validation. Silver Spring, MD: FDA; 2001:1-22. Available at: https:\/\/www.fda.gov\/downloads\/Drugs\/Guidance\/ucm070107.pdf\/ Accessed October 3, 2017."},{"issue":"2","key":"10.1016\/j.xphs.2017.08.024_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jconrel.2007.12.018","article-title":"Potential of solid lipid nanoparticles in brain targeting","volume":"127","author":"Kaur","year":"2008","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2017.08.024_bib21","first-page":"363","article-title":"Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in\u00a0vivo pharmacodynamic studies using rat electroshock model","volume":"6","author":"Eskandari","year":"2011","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"10.1016\/j.xphs.2017.08.024_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ijpharm.2008.03.029","article-title":"Intranasal nanoemulsion based brain targeting drug delivery system of risperidone","volume":"358","author":"Kumar","year":"2008","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2017.08.024_bib23","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijpharm.2009.06.019","article-title":"Nanoparticles for direct nose-to-brain delivery of drugs","volume":"379","author":"Mistry","year":"2009","journal-title":"Int J Pharm"},{"issue":"4589","key":"10.1016\/j.xphs.2017.08.024_bib24","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.6338589","article-title":"Alzheimer's disease: a disorder of cortical cholinergic innervation","volume":"219","author":"Coyle","year":"1983","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.xphs.2017.08.024_bib25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0014-2999(99)00643-3","article-title":"Effect of rivastigmine on scopolamine-induced memory impairment in rats","volume":"383","author":"Bejar","year":"1999","journal-title":"Eur J Pharmacol"},{"issue":"23","key":"10.1016\/j.xphs.2017.08.024_bib26","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S1359-6446(02)02529-1","article-title":"Nasal drug delivery: new developments and strategies","volume":"7","author":"Illum","year":"2002","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.1016\/j.xphs.2017.08.024_bib27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.peptides.2005.09.008","article-title":"Pharmacokinetics, toxicity of nasal cilia and immunomodulating effects in Sprague\u2013Dawley rats following intranasal delivery of thymopentin with or without absorption enhancers","volume":"27","author":"Wang","year":"2006","journal-title":"Peptides"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917306251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354917306251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T16:37:28Z","timestamp":1575304648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354917306251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0022354917306251"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2017.08.024","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nose to Brain Delivery of Rivastigmine by In Situ Gelling Cationic Nanostructured Lipid Carriers: Enhanced Brain Distribution and Pharmacodynamics","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2017.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}